Arvinas, Inc.

NasdaqGS ARVN

Arvinas, Inc. Price to Earnings Ratio (P/E) on January 14, 2025

Arvinas, Inc. Price to Earnings Ratio (P/E) is NA on January 14, 2025, a NA change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Arvinas, Inc. 52-week high Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Arvinas, Inc. 52-week low Price to Earnings Ratio (P/E) is NA on January 14, 2025, which is NA below the current Price to Earnings Ratio (P/E).
Arvinas, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is NA.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: ARVN

Arvinas, Inc.

CEO	Dr. John G. Houston Ph.D.
IPO Date	Sept. 27, 2018
Location	United States
Headquarters	5 Science Park
Employees	445
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Key trends

Past 5 years